Satellos Bioscience Inc.
MSCLF$188M
Micro CapNASDAQBiotechnology🇺🇸North America14 employees
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Mar 31, 2026
24dMarket Overview
Stock performance and key metrics
MSCLF News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SAT-3247 | Phase 2 | Duchenne Muscular Dystrophy | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply